Who are R-GemOx's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, chemotherapy of mFOLFOX6 or FOLFIRI, Gemcitabine-Cisplatin chemotherapy, Pegylated liposomal doxorubicin hydrochloride, Chemotherapy+Pembrolizumab., Doxorubicin hydrochloride liposome.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r-gemox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

R-GemOx — Competitive Intelligence Brief

R-GemOx (R-GemOx) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

phase 3 chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

R-GemOx (R-GemOx) — Hutchmed. R-GemOx is a combination of gemcitabine and oxaliplatin, used to treat various cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
R-GemOx TARGET	R-GemOx	Hutchmed	phase 3	chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
Gemcitabine-Cisplatin chemotherapy	Gemcitabine-Cisplatin chemotherapy	Simcere Pharmaceutical Co., Ltd	marketed	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking)
Pegylated liposomal doxorubicin hydrochloride	Pegylated liposomal doxorubicin hydrochloride	M.D. Anderson Cancer Center	marketed	Anthracycline chemotherapy (liposomal formulation)	Topoisomerase II, DNA
Chemotherapy+Pembrolizumab.	Chemotherapy+Pembrolizumab.	Tang-Du Hospital	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); chemotherapy targets DNA
Doxorubicin hydrochloride liposome	Doxorubicin hydrochloride liposome	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	marketed	Anthracycline chemotherapy agent (liposomal formulation)	DNA topoisomerase II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

Pfizer · 3 drugs in this class
Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Hutchmed · 1 drug in this class
Prof. Massimo Aglietta · 1 drug in this class
Sanofi · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R-GemOx — Competitive Intelligence Brief. https://druglandscape.com/ci/r-gemox. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab